Literature DB >> 24909312

Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.

Giuseppe Lombardi1, Anna Luisa Di Stefano2, Patrizia Farina3, Vittorina Zagonel3, Emeline Tabouret4.   

Abstract

The frequency of metastatic brain tumors has increased over recent years; the primary tumors most involved are breast cancer, lung cancer, melanoma and renal cell carcinoma. While radiation therapy and surgery remain the mainstay treatment in selected patients, new molecular drugs have been developed for brain metastases. Studies so far report interesting results. This review focuses on systemic cytotoxic drugs and, in particular, on new targeted therapies and their clinically relevant activities in brain metastases from solid tumors in adults.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain metastases; Breast cancer; Lung cancer; Melanoma; Renal cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24909312     DOI: 10.1016/j.ctrv.2014.05.007

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  24 in total

1.  Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Authors:  Chii Chii Chew; Salby Ng; Yun Lee Chee; Teng Wai Koo; Ming Hui Liew; Evelyn Li-Ching Chee; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño; Ignacio Segarra
Journal:  Invest New Drugs       Date:  2017-03-11       Impact factor: 3.850

2.  Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.

Authors:  Ming Hui Liew; Salby Ng; Chii Chii Chew; Teng Wai Koo; Yun Lee Chee; Evelyn Li-Ching Chee; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño; Ignacio Segarra
Journal:  Invest New Drugs       Date:  2017-01-09       Impact factor: 3.850

3.  ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Authors:  Debu Tripathy; Sara M Tolaney; Andrew D Seidman; Carey K Anders; Nuhad Ibrahim; Hope S Rugo; Chris Twelves; Veronique Dieras; Volkmar Müller; Mary Tagliaferri; Alison L Hannah; Javier Cortés
Journal:  Future Oncol       Date:  2019-05-10       Impact factor: 3.404

Review 4.  A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Authors:  Tao Jiang; Chunxia Su; Shengxiang Ren; Federico Cappuzzo; Gaetano Rocco; Joshua D Palmer; Nico van Zandwijk; Fiona Blackhall; Xiuning Le; Nathan A Pennell; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer.

Authors:  Lina Li; Shuimei Luo; Heng Lin; Haitao Yang; Huijuan Chen; Ziyuan Liao; Wanzun Lin; Weili Zheng; Xianhe Xie
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

6.  Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.

Authors:  Evelyn Li-Ching Chee; Adeline Yi Ling Lim; Pilar Modamio; Cecilia Fernandez-Lastra; Ignacio Segarra
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-06       Impact factor: 2.441

Review 7.  Emerging strategies for treating brain metastases from breast cancer.

Authors:  David P Kodack; Vasileios Askoxylakis; Gino B Ferraro; Dai Fukumura; Rakesh K Jain
Journal:  Cancer Cell       Date:  2015-02-09       Impact factor: 31.743

8.  Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.

Authors:  Fangfang Shen; Naixin Liang; Zaiwen Fan; Min Zhao; Jing Kang; Xifang Wang; Qun Hu; Yongping Mu; Kai Wang; Mingming Yuan; Rongrong Chen; Wei Guo; Guilan Dong; Jun Zhao; Jun Bai
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

9.  Factors associated with long-term survival in central nervous system metastases.

Authors:  Bernardo Cacho-Díaz; Héctor Spínola-Maroño; Alberto González-Aguilar; Oscar Arrieta
Journal:  J Neurooncol       Date:  2018-07-12       Impact factor: 4.130

Review 10.  Sunitinib Possible Sex-Divergent Therapeutic Outcomes.

Authors:  Ignacio Segarra; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.